Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Effect on fertility: via oral route
Dose descriptor:
NOAEL
0.3 mg/kg bw/day
Additional information

The study, Waalkens-Berendsen, D. H. (2003), was performed in compliance with GLP and to the OECD guideline 421. Accordingly the study was assigned a reliability score of 1 and considered reliable and adequate for assessment. The study a single-generation reproduction screening study, noted that any influence of dibutyltin chloride on reproduction occurred only at maternally toxic levels; a maternal NOAEL of ca. 0.3 mg/kg bw/day was estimated.


Short description of key information:
The following study has been submitted to address the toxicity to reproduction endpoint:

Waalkens-Berendsen, D. H. (2003). Dibutyldichlorostannane (CAS # 683-18-1): Reproduction/developmental toxicity screening test in rats. Testing laboratory: TNO Nutrition and Food Research. Report no.: V 4906. Owner company: Organotin Environmental Programme (ORTEP) Association, Stabilizer Task Force. Report date: 2003-12-04.

The study has been allocated a Klimisch score of 1 and is considered to be sufficiently reliable and applicable for the regulatory purpose to be used as the key study for this endpoint.

Effects on developmental toxicity

Description of key information
The following studies have been submitted to address the developmental toxicity endpoint:
Waalkens-Berendsen, D. H. (2003). Dibutyldichlorostannane (CAS # 683-18-1): Reproduction/developmental toxicity screening test in rats. Testing laboratory: TNO Nutrition and Food Research. Report no.: V 4906. Owner company: Organotin Environmental Programme (ORTEP) Association, Stabilizer Task Force. Report date: 2003-12-04.
Osterburg I (1993). Dibutyltin dichloride Oral (gavage) teratogenicity study in the rat.
Ema M & Harazono A (2000). Adverse effects of dibutyltin dichloride on initiation and maintenance of rat pregnancy. Reproductive Toxicology, 14, (2000), 451-456.
Ema et al (1991). Teratogenicity of di-n-butyltin dichloride in rats. Toxicology Letters, 58 (1991) 347-356.
Ema et al (1992). Susceptible period for the teratogenicity of di-n-butyltin dichloride in rats. Toxicology, 73 (1992) 81-92.
Ema et al (1995). Comparative Developmental Toxicity of Butyltin Trichloride, Dibutyltin Dichloride and Tributyltin Chloride in Rats. JOURNAL OF APPLIED TOXICOLOGY, VOL. 15(4), 297-302 (1995).
Ema et al (1996). Comparative Developmental Toxicity of Di-, Tri- and Tetrabutyltin Compounds after Administration during Late Organogenesis in Rats. JOURNAL OF APPLIED TOXICOLOGY, VOL. 16(1), 71-76 (1996).
Noda T et al (1993). Teratogenic effects of various di-n-butyltins with different anions and butyl(3-hydroxybutyl) tin dilaurate in rats. Toxicology, 85, 149-160.
Osterburg I (1993) has been allocated a Klimisch score of 1 and has been determined to be the key study for this endpoint. All other references have been allocated a Klimisch score of 2 and are provided as supporting studies only.
Effect on developmental toxicity: via oral route
Dose descriptor:
NOAEL
5 mg/kg bw/day
Additional information

Osterburg I (1993) was performed in compliance with GLP and conducted according to the guideline OECD 414. The study was accordingly assigned a reliability score of 1 and considered adequate for assessment of the endpoint. The study was performed in Wistar rats, dosed via the oral route (gavage). The test material was determined to have a NOAEL of 1.0 mg/kg bw/day for maternal toxicity and 5.0 mg/kg bw/day for teratogenicity.

 

Seven studies were provided as supporting information and are briefly summarised below.

 

Reference: Ema M & Harazono A (2000)

Reliability and rationale for score: 2 (reliable with restrictions) Study meets generally accepted scientific standards, is well documented, and acceptable for assessment. Partial organogenetic period exposures.

Results: The study was conducted to evaluate the adverse effects of dibutyltin dichloride (DBTCl) on initiation and maintenance of pregnancy after maternal exposure during early pregnancy in rats. The NOAEL for maternal toxicity was determined to be <3.8 mg/kg/day and for teratogenicity was 15.2 mg/kg/day.

 

 

Reference: Ema et al (1991)

Reliability and rationale for score: 2 (reliable with restrictions) Study was conducted using less than the recommended number of animals (20). Purity of test material not reported. Doses were not adjusted for body weight reductions. Body weights were reduced in the two highest treatment groups; therefore, these animals may have received higher doses than reported. The number of fetuses examined for internal malformations was less than the EPA-recommended number. The two highest dose levels tested, 7.5 and 10 mg/kg, were generally lethal, killing 42% and 75% of the dams, respectively.

Results: Pregnant rats were given di-n-butyltin dichloride (DBT) by gastric intubation at a dose of 0, 2.5, 5.0, 7.5or 10.0 mg/kg on days 7-15 of pregnancy.The NOAEL for maternal toxicity was determined to be 5.0 mg/kg/day and for teratogenicity was 2.5 mg/kg/day.

 

 

Reference: Ema et al (1992)

Reliability and rationale for score: 2 (reliable with restrictions) Study meets generally accepted scientific standards, is well documented, and acceptable for assessment. Purity of test material not reported. Partial organogenetic period exposures.

Results: Pregnant rats were given di-n-butyltin dichloride (DBT) by gastric intubation at a dose of 20 mg/kgon days7-9,10-12 or 13-15 of pregnancy or at a dose of 20 or 40 mg/kg on day 6, 7, 8 or 9 of pregnancy.It could be concluded that, following maternal exposure to DBT in rats, developing offspring are not susceptible to teratogenic effects of DBT on day 6 and that day 7 is the earliest susceptible period, day 8 is the highest susceptible period and day 9 is no longer a susceptible period for teratogenesis of DBT.

 

 

Reference: Ema et al (1995)

Reliability and rationale for score: 2 (reliable with restrictions) Study meets generally accepted scientific standards, is well documented, and acceptable for assessment. Purity of test material not reported. Partial organogenetic period exposures.

Results: Butyltin trichloride (BT), dibutyltindichloride (DBT)and tributyltin chloride (TBT) were compared for their developmental toxicity including teratogenic potential following administration during the susceptible period for the teratogenesis of DBT. Pregnant rats were given DBT at a doseof 10or 15 mg/kgby gastric intubation on days 7and 8 of pregnancy.Treatmentwith DBT resulted in a significantly lower maternal weight gain, lower fetal weight and higher postimplantation embryolethality. A significantly and markedly increased incidence of fetuses with malformations, such as exencephaly, cleft jaw, cleft lip, ankyloglossia, club foot, deformityofthe vertebral column in the cervical and thoracic regions and of the ribs and ano- ormicrophthalmia, was observedinboth groupstreated with DBT.It could be concluded that BT, DBT and TBT are differentin thesusceptibility andspectrumof developmentaltoxicity.

 

 

Reference: Ema et al (1996)

Reliability and rationale for score: 2 (reliable with restrictions) Study meets generally accepted scientific standards, is well documented, and acceptable for assessment. Purity of test material not reported. Partial organogenetic period exposures.

Results: Dibutyltin dichloride (DBT), tributyltin chloride (TrBT) and tetrabutyltin (TeBT) were compared fortheir developmental toxicity and teratogenic potential following administration during the susceptibleperiod for teratogenesis of TrBT.

Pregnant rats were given DBT at a dose of 165 or 330µmol/kg on days 13-15 of pregnancy. The findings of the study suggest that DBT has no teratogenic effect when administered during late organogenesis at doses that induced overt maternal toxicity.It could be concluded that there is a difference in the manifestationand degree of developmental toxicity between DBT, TrBT and TeBT.

 

 

Reference: Noda T et al (1993)

Reliability and rationale for score: 2 (reliable with restrictions) The number of animals and dose groups used in this study were less than the recommended amounts in OECD Guideline 414. Study meets generally accepted scientific standards, is well documented, and acceptable for assessment. Partial organogenetic period exposures.

Results: In the oral (gavage) teratogenicity study in the rat the test material was determined, not to be toxic maternally, but was teratogenic to developing fetuses. The NOAEL is therefore 24.3 mg/kg for maternal toxicity and <24.3 mg/kg for teratogenicity.

 

 

Reference: Waalkens-Berendsen DH (2003)

Reliability and rationale for score: 1 (reliable without restriction) The study was performed in compliance with GLP and in accordance with the guideline OECD 421.

Results:In the Reproduction/developmental toxicity screening test in rats (TNO study number: V 4906) the test material was determined to have a NOAEL for general toxicity established on the low-dose level of 5 mg/kg diet and the NOAEL for reproductive toxicity was established at the mid-dose level of 30 mg/kg diet. No mortalities were observed. No clinical signs were observed in the male and female animals from the start of the study until sacrifice. Examination of the thymus revealed severe to very severe lymphoid depletion in 12/12 high-dose females, and moderate to severe lymphoid depletion in 6/12 (pregnant) mid-dose females.Three females showed late resorptions (autolytic fetuses) in the uterus during necropsy.

Overall summary:

In several studies of development and teratogenicity, the substance as well as several other organotins were repeatably and reliably associated with a syndrome of malformations of the oroglossal region. Malformations appear to be limited to dose levels also associated with maternal toxicity, and result from exposure in a specific limited window during pregnacy (maximal on day 7), but not in the late pregnancy.

In a single-generation reproduction screening OECD 421 study, any influence of dibutyltin chloride on reproduction/developmental toxicity occurred only at maternally toxic levels. A maternal NOAEL of ca. 0.3 mg/kg bw/day was estimated, while no effects on offspring up to day 4 of lactation were observed up to the higher dose of approximately 2 mg/kg bw/day.

The data available are consistent with conclusions of the SPCFC (2004) review of organotins, that Dibutyltin elicts teratogenicity and embryotoxicity in rats at dose levels inducing also maternal toxicity. Although SPCFC concluded a NOAEL at 5 mg/kg bw/day for dibutyltin chloride, the single-generation study by Waalkens-Berendson (2003) was not available to SPCFC and the NOAEL from that study (0.3 mg/kg bw/day, for maternal toxicity, based on the most sensistive end point i.e. thymus weight) would appear closer to the NOAEL for organotins as a group set by SPCFC. A further study of teratogenicity in the rat is also available (Osterberg 1993) including consideration of thymus weight in dams, with NOAEL for maternal toxicity at 1 mg/kg bw/day and LOAEL at 2.5 mg/kg bw/day; this study is also not included in the EFSA/SPCFC review.

Justification for classification or non-classification

The substance is classified with Repro. Cat. 2; R60 -61 according to Directive 67/548/EEC. According to Regulation (EC) no 1272/2008 the test substance would be classified as a Repr. 1B with Hazard statement: H360FD: May damage fertility or the unborn child and should be accompanied with the signal word 'Danger'.

Additional information